HER2 in uterine carcinosarcoma: testing platforms and implications for targeted therapy


Navin Maredia, Sharon Wu, Alex Farrell, Matthew Oberley, Lauren Thomaier, Nathaniel Jones, Thomas Herzog, Premal Thaker, Matthew Powell, Tenley Klc, Britt K. Erickson

Key Finding:

Increased HER2 positivity was detected via CISH testing compared to IHC and NGS, which may reflect the heterogeneity of HER2 amplification due to mixed histology between the sarcoma and carcinoma portion of the tumor. 

Download Publication